Bio-Rad Historical Cash Flow
| BIO-B Stock | USD 334.85 38.50 10.31% |
Analysis of Bio-Rad Laboratories cash flow over time is an excellent tool to project Bio Rad Laboratories future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Free Cash Flow of 229.2 M or Begin Period Cash Flow of 271.2 M as it is a great indicator of Bio-Rad Laboratories ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Bio Rad Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bio Rad Laboratories is a good buy for the upcoming year.
Bio-Rad |
About Bio-Rad Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Bio-Rad balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Bio-Rad's non-liquid assets can be easily converted into cash.
Bio-Rad Laboratories Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Bio Rad Laboratories to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Bio-Rad Laboratories operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most accounts from Bio-Rad Laboratories' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Bio Rad Laboratories current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Bio-Rad Laboratories' Stock Based Compensation is projected to increase significantly based on the last few years of reporting. The current year's Free Cash Flow is expected to grow to about 229.2 M, whereas Change To Inventory is projected to grow to (44 M).
Bio-Rad Laboratories cash flow statement Correlations
Click cells to compare fundamentals
Bio-Rad Laboratories Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio-Rad Laboratories cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 24.2M | (52.1M) | 46.1M | (158.8M) | (46.3M) | (44.0M) | |
| Change In Cash | 228.5M | 4.5M | (196.0M) | (36.6M) | (30.2M) | (28.7M) | |
| Stock Based Compensation | 35.6M | 41.6M | 51.2M | 60.9M | 61.3M | 64.4M | |
| Free Cash Flow | 359.4M | 476.4M | 535.7M | 80.3M | 218.3M | 229.2M | |
| Change In Working Capital | 55.4M | 51.7M | 13.9M | (407.0M) | (127.6M) | (121.3M) | |
| Begin Period Cash Flow | 434.2M | 662.7M | 667.1M | 471.1M | 434.5M | 271.2M | |
| Other Cashflows From Financing Activities | 5.9M | 3.9M | (2.4M) | 3.5M | 3.5M | 3.4M | |
| Depreciation | 134.2M | 138.1M | 133.8M | 137.3M | 192.4M | 202.0M | |
| Other Non Cash Items | (1.5B) | (3.4B) | (3.7B) | 5.3B | 1.1B | 1.1B | |
| Capital Expenditures | 98.5M | 98.9M | 120.8M | 114.2M | 156.7M | 84.5M | |
| Total Cash From Operating Activities | 457.9M | 575.3M | 656.5M | 194.4M | 374.9M | 393.7M | |
| Net Income | 1.8B | 3.8B | 4.2B | (3.6B) | (637.3M) | (605.5M) | |
| Total Cash From Financing Activities | (22.8M) | (523.0M) | (55.4M) | 973.6M | (425.6M) | (404.4M) | |
| End Period Cash Flow | 662.7M | 667.1M | 471.1M | 434.5M | 404.4M | 286.4M | |
| Sale Purchase Of Stock | (28M) | (100.0M) | (50.0M) | (215.7M) | (428.7M) | (407.3M) | |
| Change To Account Receivables | 1.6M | (15M) | (20.4M) | (87.4M) | 11.4M | 12.0M | |
| Investments | (39.9M) | 119.6M | (538.2M) | (994.2M) | (110.5M) | (116.1M) | |
| Change Receivables | 31.7M | 21.5M | 35.3M | 68.2M | 78.4M | 82.3M | |
| Net Borrowings | (643K) | (426.9M) | (3.0M) | 1.2B | 1.4B | 1.4B | |
| Total Cashflows From Investing Activities | (208.9M) | (60.3M) | (784.4M) | (1.2B) | (1.1B) | (1.0B) | |
| Exchange Rate Changes | (655K) | 2.2M | 12.4M | (12.6M) | (11.4M) | (10.8M) | |
| Cash And Cash Equivalents Changes | 228.5M | 4.5M | (196.0M) | (39.6M) | (45.5M) | (43.2M) | |
| Cash Flows Other Operating | 426.2M | 553.8M | 621.2M | 126.3M | 145.2M | 137.9M | |
| Change To Netincome | (2.0B) | (4.5B) | (3.8B) | 5.3B | 4.7B | 5.0B | |
| Change To Operating Activities | 73.5M | 12.1M | 13.9M | (26.8M) | (30.8M) | (29.3M) | |
| Change To Liabilities | 460.8M | 1.1B | 1.2B | (1.3B) | (1.5B) | (1.5B) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bio Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio-Rad Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock:Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..